BETA: Please send your feedback!
Eagle Pharmaceuticals
EGRX:NAS
Pharmaceuticals: Other
$927.17mm
SMALL cap
$62.38
(0.04%)
0.53%
since start of 2019
21.19
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- 3
-
CF
-
PP
-
WC
-
DP
-
CH
-
ES
-
WS
-
CG
-
EP
-
CM
-
FL
-
GD
- —
- 1
- 2
- 3
- 4
- 5
About
Pharmaceuticals: Other
Founded 2007
Eagle Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the provision of injectable products. Its activities include development and commercialization of pharmaceutical products for the treatment of areas such as critical care, orphan diseases, and oncology. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.
website
Headquarters
Executives
| Name | Title | Gender |
| Scott L. Tarriff, MBA | Chief Executive Officer & Director | Male |
| Peter E. Grebow, PhD | Executive Vice President-Research & Development | Male |
| David E. Riggs, MBA | Chief Financial Officer | Male |
| David M. Pernock | President & Chief Commercial Officer | Male |
| Adrian Hepner, MD, PhD | Executive Vice President & Chief Medical Officer | Male |
| Michael Graves | Chairman | Male |
| Steven L. Krill, PhD | Chief Scientific Officer & Executive VP | Male |
| John LaRocca | Chief Compliance Officer, EVP & General Counsel | Male |
Mindful Investing Summary
- —
- 1
- 2
- 3
- 4
- 5
-
Carbon Footprint — N/A
-
Pollution Prevention — N/A
-
Water Conservation — N/A
-
Data & Privacy Protection — N/A
-
Consumer Health, Wellness & Safety — N/A
-
Employee Ownership, Satisfaction, Benefits & Pay — N/A
-
Workplace Health and Safety — N/A
-
Integrity of Corporate Governance — N/A
-
Ethical Practices — N/A
-
Usage of Conflict Materials — N/A
-
Forced Labor — N/A
-
Diversity of Corporate Leadership 1
Eagle Pharmaceuticals - Competitors and Related Companies
How Eagle Pharmaceuticals stacks up to its peers in the Pharmaceuticals: Other industry or with competing business segments.
Eagle Pharmaceuticals
EGRX:NAS
Pharmaceuticals: Other
$927.17mm
SMALL cap
$62.38
(0.04%)
0.53%
since start of 2019
21.19
Madrigal Pharmaceuticals
MDGL:NAS
Pharmaceuticals: Other
$1.38bn
SMALL cap
$89.14
(1.26%)
-0.20%
since start of 2019
-24.99
Amgen
AMGN:NAS
Biotechnology
$123.09bn
MEGA cap
$205.25
(2.32%)
0.07%
since start of 2019
16.15
Bristol-Myers Squibb
BMY:NYS
Pharmaceuticals: Major
$91.01bn
MEGA cap
$55.63
(2.44%)
0.06%
since start of 2019
14.59
Johnson & Johnson
JNJ:NYS
Pharmaceuticals: Major
$343.09bn
MEGA cap
$130.00
(1.98%)
0.02%
since start of 2019
—
Novartis
NOVN-CH:SWX
Pharmaceuticals: Major
$60.48mm
MEGA cap
$2.32
(-0.03%)
1.39%
since start of 2019
-2.42